About Grifols

Grifols is a global healthcare company with more than 75 years of history improving the health and well-being of people around the world. We produce essential plasma medicines for patients and provide hospitals, pharmacies, and healthcare professionals with the tools, information, and services they need to efficiently deliver expert medical care.

Our three divisions–Bioscience, Diagnostic, and Hospital–develop, produce, and market innovative products and services available in more than 100 countries.

With the world's largest network of plasma donation centers, the Grifols Bioscience Division is a leading producer of plasma medicines for the treatment of rare, chronic, and sometimes life-threatening conditions. To help ensure a reliable, consistent source of plasma medicines worldwide, Grifols has an all-inclusive process that begins with plasma collection and continues through the fractionation, purification, and production at its three facilities located in Spain (Barcelona) and the United States (Clayton, North Carolina, and Los Angeles, California).

A leader in transfusion medicine, the Grifols Diagnostic Division advances patient care with diagnostic solutions to improve disease detection and management and simplify laboratory operations. The Grifols Hospital Division provides intravenous (IV) therapies, clinical nutrition products, and hospital pharmacy systems, including systems that automate drug compounding and drug inventory control systems.

Headquartered in Barcelona, Grifols employs approximately 14,700 people in 30 countries.  Ensuring quality, integrity, and safety in all activities is a crucial to our mission, as our products are of vital importance to the health and quality of life of patients we serve.

For more information, visit www.grifols.com

GrifolsGrifols

Learn about Grifols, a global healthcare company

 GrifolsUSA.com

Thrombate III® (antithrombin III [human]) is indicated for the treatment of patients with hereditary antithrombin deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.

In clinical studies, the most common adverse events were dizziness, chest discomfort, nausea, and dysgeusia.

The anticoagulant effect of heparin is enhanced by concurrent treatment with Thrombate III in patients with hereditary AT-III deficiency. Thus, in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with Thrombate III.

Thrombate III is made from human plasma. Plasma products carry a risk of transmitting infectious agents, such as viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk. No cases of transmission of viral disease or CJD have ever been identified for Thrombate III.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.